Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

During the 1980, the haemophilia centre at the Royal Hospital for Sick Children ("RHSC") in Yorkhill, Glasgow, provided haemophilia treatment to children from the Glasgow area and across the West of Scotland. 55 had Haemophilia A, 14 had Haemophilia B and 1 had von Willebrand disease.

  • Read more about During the 1980, the haemophilia centre at the Royal Hospital for Sick Children ("RHSC") in Yorkhill, Glasgow, provided haemophilia treatment to children from the Glasgow area and across the West of Scotland. 55 had Haemophilia A, 14 had Haemophilia B and 1 had von Willebrand disease.

In 1974 - 1975, at the Glasgow Royal Infirmary while commercial concentrates were in use cryoprecipitate was the predominant product.

  • Read more about In 1974 - 1975, at the Glasgow Royal Infirmary while commercial concentrates were in use cryoprecipitate was the predominant product.

From 1980, when Professor Ludlam arrived in Edinburgh, the volume of NHS concentrates used exceeded the volume of cryoprecipitate for the first time.

  • Read more about From 1980, when Professor Ludlam arrived in Edinburgh, the volume of NHS concentrates used exceeded the volume of cryoprecipitate for the first time.

In Edinburgh the principal product used in 1979 was cryoprecipitate.

  • Read more about In Edinburgh the principal product used in 1979 was cryoprecipitate.

In Edinburgh the principal product used in 1978 was cryoprecipitate.

  • Read more about In Edinburgh the principal product used in 1978 was cryoprecipitate.

In Edinburgh the principal product used in 1977 was cryoprecipitate.

  • Read more about In Edinburgh the principal product used in 1977 was cryoprecipitate.

In Edinburgh the principal product used in 1976 was cryoprecipitate.

  • Read more about In Edinburgh the principal product used in 1976 was cryoprecipitate.

Speakers from the Medical Ethics Experts Panel held that it was ethically wrong not to promptly provide patients with the outcomes of their diagnosis and test results.

  • Read more about Speakers from the Medical Ethics Experts Panel held that it was ethically wrong not to promptly provide patients with the outcomes of their diagnosis and test results.

Speakers from the Medical Ethics Experts Panel held that it was ethically wrong not to explain the risks of treatment to patients.

  • Read more about Speakers from the Medical Ethics Experts Panel held that it was ethically wrong not to explain the risks of treatment to patients.

Evidence presented to the inquiry held that while most doctors took the view that not discussing the risks associated with blood products with patients would not result in deterring patients from using the various treatments anyway. However, Professors Farsides and Kerridge on the medical experts panel to the inquiry disagreed, stating until one has disclosed all the risks to a patient, then one cannot assume patients are making a fully informed decision.

  • Read more about Evidence presented to the inquiry held that while most doctors took the view that not discussing the risks associated with blood products with patients would not result in deterring patients from using the various treatments anyway. However, Professors Farsides and Kerridge on the medical experts panel to the inquiry disagreed, stating until one has disclosed all the risks to a patient, then one cannot assume patients are making a fully informed decision.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 68
  • Page 69
  • Page 70
  • Page 71
  • Current page 72
  • Page 73
  • Page 74
  • Page 75
  • Page 76
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.